Fresenius’ figures were mixed with Helios reporting the strongest profitability increase, whereas admissions were still below pre-pandemic levels in Germany. Kabi reported the expected slowdown despite a strong performance in Infusion Therapy. FMC suffered from a long list of negative effects. All in all, profitability was burdened by cost inflation and other negative impacts at group level.
Consensus was beaten at the top-line (+2.3%) and profitability by +3.5%.
05 May 2022
Better growth in Helios margin under the Spanish sun
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Better growth in Helios margin under the Spanish sun
Fresenius’ figures were mixed with Helios reporting the strongest profitability increase, whereas admissions were still below pre-pandemic levels in Germany. Kabi reported the expected slowdown despite a strong performance in Infusion Therapy. FMC suffered from a long list of negative effects. All in all, profitability was burdened by cost inflation and other negative impacts at group level.
Consensus was beaten at the top-line (+2.3%) and profitability by +3.5%.